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Abstract
Genome-wide association studies (GWAS) of alcohol dependence (AD) have reliably identified 
variation within alcohol metabolizing genes (e.g., ADH1B) but have inconsistently located other 
signals, which may be partially attributable to symptom heterogeneity underlying the disorder. We 
conducted GWASs of DSM-IV AD (primary analysis), DSM-IV AD criterion count (secondary 
analysis), and individual dependence criteria (tertiary analysis) among 7,418 (1,121 families) 
European American (EA) individuals from the Collaborative Study on the Genetics of Alcoholism 
(COGA). Trans-ancestral meta-analyses combined these results with data from 3,175 (585 
families) African American (AA) individuals from COGA. In the EA GWAS, three loci were 
genome-wide significant: rs1229984 in ADH1B for AD criterion count (p=4.16E-11) and Desire 
to cut drinking (p=1.21E-11); rs188227250 (chromosome 8, Drinking more than intended, 
p=6.72E-09); rs1912461 (chromosome 15, Time spent drinking, p=1.77E-08). In the trans-
ancestral meta-analysis, rs1229984 was associated with multiple phenotypes and two additional 
loci were genome-wide significant: rs61826952 (chromosome 1, DSM-IV AD, p=8.42E-11); 
rs7597960 (chromosome 2, Time spent drinking, p=1.22E-08). Associations with rs1229984 and 
rs18822750 were replicated in independent datasets. Polygenic risk scores derived from the EA 
GWAS of AD predicted AD in two EA datasets (p<0.01; 0.61-1.82% of variance). Identified novel 
variants (i.e., rs1912461, rs61826952) were associated with differential central evoked theta power 
(loss minus gain; p=0.0037) and reward-related ventral striatum reactivity (p=0.008), respectively. 
This study suggests that studying individual criteria may unveil new insights into the genetic 
etiology of AD liability.
Keywords
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polygenic risk score; Event-Related Theta Oscillations (ERO); functional Magnetic Resonance 
Imaging (fMRI)
INTRODUCTION
Alcohol dependence (AD), characterized by excessive drinking and diagnosed using features 
such as loss of control over drinking and excessive consumption despite negative 
consequences, is one of the most common and costly public health problems worldwide 1. In 
the United States (U.S.), 12.5% of the population meets criteria for DSM-IV AD1,2. AD is a 
complex disease with both genetic and environmental underpinnings and an estimated 
heritability around 50% 3. Identification of loci associated with AD liability could provide 
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new insights into the biological mechanisms underlying this serious disorder and lead to new 
therapeutic pathways.
Individual genome-wide association studies (GWAS) of AD have been relatively modest in 
size (but see a recent large publication using International Classification of Disease codes4) 
and have failed to identify consistently replicable loci 5, with the exception of variants 
within the alcohol metabolizing genes, notably ADH1B, and to a lesser degree, ADH1C. A 
recent large GWAS meta-analysis of 14,904 AD cases and 37,944 controls, which includes 
some of the samples used in this study, also only detected genome-wide significant (GWS) 
association with rs1229984 (Europeans) and rs2066702 (African-Americans); both SNPs are 
in ADH1B6. However, when examining a broader definition of alcohol use disorders from 
medical records, loci in additional genes have recently been identified4. We have previously 
conducted GWAS of AD-related phenotypes in smaller subsets of the data used in the 
present study, but results have eluded replication and power to detect rs1229984 has been 
low (e.g., for AD in a subset of 1884 unrelateds7, for AD, criterion count and criteria in 
2010-2,322 individuals from 118 families8,9).
One possible challenge to identification of novel loci contributing to AD susceptibility may 
be the heterogeneity underlying the diagnosis of AD. Meeting criteria for DSM-IV AD 
requires that an individual endorse any three (or more) of the seven DSM-IV criteria 
(Tolerance; Withdrawal; Drinking more than intended; Desire to cut drinking; Giving up 
activities; Time spent drinking; Drinking despite problems) during the same 12-month 
period. However, psychometric literature points to the differential severity and contribution 
of individual criteria10. An approach to reduce diagnostic heterogeneity may be the analysis 
of individual DSM-IV criteria in addition to the overall AD diagnosis. Twin studies have 
suggested that the individual criteria that comprise the AD diagnosis are heritable 11-13. For 
instance, Kendler and colleagues showed the heritability of individual criteria ranged from 
36% (Desire to cut drinking) to 59% (Time spent drinking) 14. Another study found that 
heritability of individual criteria (in a subset of the data used here) were between 29% 
(Tolerance) and 59% (Drinking more than intended) 9. Genomic data also support this 
variability with Palmer et al reporting a SNP-based heritability ranging from 13% (Time 
spent drinking) to 34% (Tolerance) 15. The variability across these estimates likely arises 
from ascertainment (e.g., ascertained for addiction vs. twin epidemiologic sample) and the 
analytic approach (e.g., using SNPs vs. family relatedness). In addition, in one study, the 
observed associations with ADH1B loci were also differentially attributable to Tolerance, 
Withdrawal, Drinking more than intended, and Time spent drinking, relative to other criteria 
16.
Another strategy to improve the ability to detect variants contributing to DSM-IV AD is to 
consider the severity of the AD. One approach is to analyze a quantitative variable 
representing the total number of criteria that a person endorses. Although multiple 
combinations of criteria and study characteristics may result in a similar criterion count 17, 
especially when fewer criteria are endorsed 18, this proxy for AD severity has been 
successfully employed in previous studies 19,20 as it makes no assumptions about the cut-off 
of three or more criteria as an index of “affection status” nor does it equate individuals with 
1-2 criteria with those who endorse no criteria during their lifetime.
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In this study, we sought to harness the phenotypic richness of the high density alcohol 
dependent families recruited as part of the Collaborative Study on the Genetics of 
Alcoholism (COGA) to perform a series of complementary analyses designed to identify 
variation contributing to the risk of AD. Our primary GWAS focused on DSM-IV AD 
diagnosis, a clinically validated measure of pathological drinking that is commonly used in 
GWAS 6. We also conducted secondary GWAS of AD severity defined as the count of these 
criteria (range 0-7), as this quantitative phenotype has been shown to facilitate identification 
of GWS loci over the binary diagnostic measure of DSM-IV AD (e.g.,21). In tertiary 
analyses, we conducted exploratory GWASs of the seven individual DSM-IV AD criteria, in 
order to assess which criteria were the most significant contributors to the overall findings 
observed for DSM-IV AD diagnosis and criterion count, and further, examine whether novel 
loci emerged for individual criteria. To identify common variants associated with these 
phenotypes, a GWAS was performed in the European American (EA, n=1,114 families; “EA 
GWAS”) subsample of COGA, followed by a trans-ancestral genome-wide meta-analysis of 
the EA and African American (AA; N=585 families) subsamples. GWS (p<5E-8) findings 
were tested for replication in three independent datasets (Study of Addiction: Genetics and 
Environment (SAGE)22, Alcohol Dependence GWAS in European and African Americans 
(Yale-Penn)21, and the Australian Twin-family Study of Alcohol Use Disorder (OZALC)23, 
which included EA (OZ-ALC, SAGE) and AA (SAGE, Yale-Penn) individuals. Polygenic 
risk scores (PRS) were created from the COGA EA GWAS and used to predict AD in EAs 
from SAGE and OZ-ALC. We also performed gene based analyses using COGA EA GWAS. 
Lastly, to probe the potential neural correlates of the GWS variants associated with aspects 
of AD, we tested whether GWS variants identified in the primary (DSM-IV AD), secondary 
(AD criterion count) or tertiary (individual criteria) analyses were associated with two 
reward-related neural phenotypes, one within a subset of young individuals from COGA 
24and another within the independent Duke Neurogenetics Study 25. The overall design of 
this study is shown in Figure 1.
MATERIALS AND METHODS
Collaborative Study on the Genetics of Alcoholism
Sample: COGA recruited AD probands from inpatient and outpatient AD treatment 
facilities in seven sites. Community-based families were also recruited from a variety of 
sources26. Institutional review boards from all seven sites approved the study and all 
participants provided informed consent. COGA participants were administered the Semi-
Structured Assessment for the Genetics of Alcoholism (SSAGA), a poly-diagnostic 
interview 27,28. Individuals below age 18 were administered the child version of the SSAGA, 
the C-SSAGA. If an individual was interviewed more than once, data from the interview 
with the maximum total number of endorsed DSM-IV AD criteria were utilized.
Measures: To avoid the inclusion of individuals with high genetic risk who do not drink 
for personal, social or cultural reasons, only individuals who reported ever drinking at least 
one full drink of alcohol in their lifetime were included in analyses (EA: N=7,418; AA: 
N=3,175).
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The primary phenotype in this study was diagnosis of DSM-IV AD29. Individuals meeting 
criteria for DSM-IV AD at age 15 or older were coded as affected. Individuals were coded 
as unaffected if they met all of the following criteria: 1) ≥ 21 years; 2) endorsed < 2 criteria 
for DSM-IV dependence or abuse for alcohol, and 3) endorsed < 2 criteria for DSM-IV 
dependence or abuse for cocaine, opioids, marijuana, sedatives, and stimulants. Affected 
individuals <15 years of age and unaffected individuals <21 years of age were excluded. 
Exclusions for age removed affected individuals with early onset AD who might be 
etiologically distinct, due to the potentially stronger role of environmental than genetic 
influences 30. For unaffected individuals, exclusion of those < 21 years of age removed those 
who may not have passed through the peak period of risk for the onset of AD 31,32. Due to 
the strong evidence for shared genetic influences on alcohol and other forms of substance 
use disorders, individuals who did not meet criteria for AD but endorsed multiple abuse or 
dependence criteria for other substances were also excluded from the analysis.
The secondary phenotype in this study was the sum of endorsed criteria out of the seven 
DSM-IV AD criteria.
Tertiary phenotypes included each of the seven individual DSM-IV AD criteria. Individuals 
who drank alcohol but did not endorse that specific criterion were coded as unaffected.
Phenotypic analysis: Tetrachoric correlations (for binary phenotypes) and polychoric 
correlations (for binary and count phenotypes) were calculated using SAS9.4 (SAS Institute 
Inc. Cary, NC, USA). We conducted an item response analysis in Mplusv833, using a two-
parameter logistic model, to confirm the uni-dimensionality underlying the seven criteria 
and to examine the discrimination and difficulty associated with each criterion (see 
Supplemental Text).
Genotyping, Quality Review, Ancestry and Imputation: Four different genome-
wide genotyping arrays were used in COGA: 1. COGA case/control data were genotyped on 
the Illumina Human1M array (Illumina, San Diego, CA, USA) at the Center for Inherited 
Disease Research (CIDR), Johns Hopkins University 7; 2. COGA European American 
family data were genotyped on the Illumina Human OmniExpress 12V1 array (Illumina, San 
Diego, CA, USA) at the Genome Technology Access Center, Washington University School 
of Medicine 9,34; 3. COGA AA family data were genotyped on the Illumina 2.5M array 
(Illumina, San Diego, CA, USA) at CIDR 35; 4. The remaining samples were genotyped on 
the Smokescreen genotyping array (Biorealm LLC, Walnut, CA, USA) at Rutgers 
University. Among these arrays, two to 127 samples were genotyped on at least two different 
arrays with pairwise concordance rates all > 99.18%.
A set of 47,000 variants genotyped on all arrays and meeting the following four criteria: 
common (defined as MAF > 10% in the combined sample), independent (defined as R2 < 
0.5), high quality (missing rate < 2% and Hardy-Weinberg Equilibrium (HWE) P-values > 
0.001), were used to assess duplicate samples included on multiple arrays and also to 
confirm the reported pedigree structure. Family structures were altered as needed, and 
genotypes were checked for Mendelian inconsistencies using Pedcheck 36 with the revised 
family structure. Genotype inconsistencies were set to missing. The same set of 47,000 
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variants was also employed to calculate principal components (PCs) using Eigenstrat 37 and 
1000 Genomes (Phase 3, version 5). Based on the first two PCs, each individual was then 
assigned a race classification (AA, EA, and Other). To maximize the value of the multiplex 
family recruitment strategy of COGA, family-based analyses were performed. Families were 
assigned a family-based race, according to the majority of individual-based race in that 
family.
All samples were imputed to 1000 Genomes using the cosmopolitan reference panel (Phase 
3, version 5, NCBI GRCh37) using SHAPEIT2 38 then Minimac3 39 within each array. Only 
variants with non A/T or C/G alleles, missing rates < 5%, MAF > 3%, and HWE p values > 
0.0001 were used for imputation. Imputed variants with R2 < 0.30 were excluded, and 
genotype probabilities were converted to genotypes if probabilities >= 0.90. Pedcheck 36 
was used again to detect and clean Mendelian inconsistences for imputed variants. All 
genotyped and imputed variants with missing rates< 25%, MAF >= 1% and HWE p values > 
1E-6 were included in analyses. 8,021,023 and 6,832,792 genotyped and imputed variants 
passed QC and were included in COGA EA and trans-ancestral (EA+AA) meta-analysis 
respectively.
Genome-wide association studies and meta-analysis: Discovery GWAS were 
focused on the EA subsample and a trans-ancestral meta-analysis of GWAS summary 
statistics from the COGA AA and EA subsamples (EA+AA; see Figure 1). Even though a 
GWAS was conducted in the AA subsample, results were only used in the trans-ancestral 
meta-analysis. Due to the strict definition of AD controls, the individual AA subsample was 
too small for use as a discovery sample (both cases and controls had a sample size < 1000; 
full results available upon request). For binary traits, association analysis was performed 
using a generalized estimating equation (GEE) framework (with a binomial probability 
distribution) to control for relatedness with each family treated as a cluster. For the criterion 
count measure, a liner mixed effects model was fit to continuously distributed data with 
family relationship adjusted through a kinship matrix. The R package GWAF 40 was used to 
test both models. Birth cohort (birth year: 1890-1929; 1930-1949; 1950-1969; >=1970) was 
a stronger predictor of alcohol dependence than was age (see also: Grucza et al., 2008 41), 
and hence was selected along with sex, GWAS array indicator, and the first four ancestral 
principal components (as in a prior study by 34) as covariates in the model. In GWS regions, 
conditional analyses were performed by including the most significant variant in the region 
as a covariate to evaluate whether a single locus explained the association signal. The trans-
ancestral (EA+AA) meta-analysis was performed using inverse-variance weighting in 
METAL 42. As implemented in METAL, genomic control, which was estimated by 
comparing the median test statistics to those expected by chance alone, was applied to the 
GWAS of COGA AA and COGA EA. For the trans-ancestral meta-analysis (EA+AA), 
genomic control was applied to the standard errors of the effect sizes. All genomic control 
estimations were implemented in METAL. Only GWS variants (p <5E-8) were evaluated in 
replication samples. As we tested seven individual criteria for the tertiary analyses, a matrix 
of the phenotypic correlations between these criteria in the EA participants (Supplemental 
Table 1B) was spectrally decomposed using matSpD 43,44 resulting in 3 effectively 
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independent tests and thus a revised GWS p value threshold of 1.67E-8 was used for the 
tertiary analyses.
Replication Samples
Three independent datasets from the database of Genotypes and Phenotypes (dbGaP) were 
used to replicate significant findings from primary, secondary and tertiary analyses: Study of 
Addiction: Genetics and Environment (non-overlapping individuals from SAGE, 
phs000092.v1.p1, https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?
study_id=phs000092.v1.p1), Alcohol Dependence GWAS in European and African 
Americans (Yale-Penn, phs000425.v1.p1, https://www.ncbi.nlm.nih.gov/projects/gap/cgi-
bin/study.cgi?study_id=phs000425.v1.p1), and the Australian Twin-family Study of Alcohol 
Use Disorder (OZALC, phs000181.v1.p1, https://www.ncbi.nlm.nih.gov/projects/gap/cgi-
bin/study.cgi?study_id=phs000181.v1.p1). Genotypic data from these samples were 
combined with genotypic data from the COGA samples to identify identical individuals 
across all datasets; overlapping subjects were retained in the discovery GWAS in COGA but 
excluded from the replication samples. Ancestry in the combined replication sample was 
determined in a manner similar to COGA. A similar definition of AD was employed where 
unaffected individuals with alcohol abuse, or other substance dependence were excluded. 
The secondary (DSM-IV AD criterion count) and tertiary (individual criteria) phenotypes 
were also coded in an identical manner. In each replication attempt, only the identical 
phenotype was tested in the replication cohort (e.g., for a variant that was GWS for one 
criterion but not others, only association with that criterion was tested in the replication 
samples). Due to the small sizes of the individual AA and EA subsets of the replication 
datasets, only the AA subsample of SAGE (SAGE-AA), EA subsample of SAGE (SAGE-
EA), AA subsample of Yale-Penn (Yale-Penn-AA), and EA subsample of OZALC 
(OZALC-EA) were included as replication samples. Empirical kinships were estimated from 
genome-wide genotypic data using the “vcf2kinship” tool as implemented in RVTESTS, 
then mixed models adjusting for empirical kinships were fitted to the data using RVTESTS 
45. For both SAGE-AA and SAGE-EA, sex and birth cohort (as defined in COGA) were 
used as covariates, while for OZALC-EA and Yale-Penn-AA, sex and age were used, as in 
publications of the parent studies. In addition, the first three PCs were included in all 
replication analyses.
Polygenic risk scores analyses
PRS analyses were performed using PRSice-2 46. EA summary statistics for the primary 
phenotype, DSM-IV AD, were used to score individuals in SAGE-EA and OZALC-EA 
datasets. Due to their well-known roles in AD, the alcohol dehydrogenase (ADH) gene 
cluster on chromosome 4 (99,985,095bp to 100,430,930bp) and ALDH2 on chromosome 12 
(112,196,532bp to 112,276,464bp) were excluded from PRS analyses to allow for estimation 
of polygenicity attributable to loci with smaller effects. A set of unrelated individuals was 
randomly selected from each replication sample (SAGE-EA: N=1,373; OZALC-EA: 
N=1,441) as required by PRSice-2. Variants located within 500kb of the index variant and 
having r2 ≥0.25 with the index variant were clumped. PRS were derived by multiplying 
effect sizes from the EA GWAS of the primary phenotype, DSM-IV AD, with the number of 
effect alleles in each individual in the target dataset. These product terms were then averaged 
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across the total number of included variants. We only used the p-value threshold of p ≤0.05 
(i.e., SNPs associated with DSM-IV AD in the discovery EA GWAS at p ≤ 0.05) in order to 
reduce the burden of multiple testing and included the same covariates as those used in 
replication analyses in each dataset.
Gene based analysis
MAGMA (De Leeuw et al., 2015), which is implemented in FUMA, a web based functional 
mapping and annotation tool (Watanabe et al., 2017) was used to perform gene based 
analysis. LD was estimated using the European samples from 1000 Genomes projects.
Neural extension I: Event-Related Theta Oscillations (ERO) analysis of GWS loci in COGA 
Prospective Sample
The COGA Prospective Sample includes offspring aged 12-34 years from COGA families, 
and was designed to assess multiple domains (e.g., clinical, neurophysiological), at 2-year 
intervals, 24. Neurophysiological analyses of reward-related theta ERO data from the most 
recent assessments were carried out in a subsample of 825 COGA AA (49.9% male, 
22.12±5.21 years of age) and 1,726 COGA EA (48.8% male, 22.26±5.21 years of age) 
young adults. Further details are in Supplemental Text.
A monetary gambling task was implemented as detailed elsewhere 47. Briefly, individuals 
bet 50¢ or 10¢ in each of 172 trials, with one of four possible outcomes: lose 50¢, lose 10¢, 
gain 50¢, or gain 10¢, with equal number of loss and gain trials (Supplemental Figure 1). 
Evoked theta ERO power (3.5–7.5 Hz) during monetary loss and gain feedback were 
measured and differential reward processing (‘loss – gain’) was derived at frontal, central, 
and parietal regions (Supplemental Figure 2). Linear regression was applied to test the 
associations between the top variants and theta ERO power after adjusting for sex, age, and 
first three PCs. We did not examine rs1229984 in ADH1B in either the COGA Prospective 
Sample or the Duke Neurogenetics Study (below) due to its well-known role in the alcohol 
metabolizing process. For the remaining four GWS loci (rs61826952 and rs7597960 from 
EA+AA meta-analysis, as well as rs188227250 and rs1912461 from the EA GWAS), three 
brain regions were tested; therefore, after multiple testing correction, the significance 
threshold was p≤0.0042 (i.e., 12 tests). Further details on data acquisition and processing are 
in Supplemental Text.
Neural extension II: Reward-related functional magnetic resonance imaging analyses of 
GWS loci in the Duke Neurogenetics Study
We examined whether GWS loci identified in analyses of alcohol-related phenotypes were 
associated with reward-related brain function among non-Hispanic AA (n=118; 72% female, 
19.6 ± 1.2 years of age) and EA (n=481; 54.5% female, 19.8±1.2 years of age) 
undergraduate students who completed the Duke Neurogenetics Study (DNS; 25; see 
Supplemental Text). For rs7597960, which was unavailable in DNS imputed data, we used a 
proxy SNP, rs2418646, which is in complete LD (i.e., r2=1.0, D’=1.0) within those of 
African and European ancestries. The chromosome 8 and 15 loci were unavailable in DNS 
imputed data and no proxies were available; due to their low MAFs, they were difficult to 
impute in this smaller sample. A number guessing paradigm was used to elicit ventral 
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striatum (VS) reactivity associated with positive and negative feedback linked to monetary 
gains and losses while blood-oxygen-level dependence (BOLD) functional magnetic 
resonance imaging (fMRI) data were acquired 48. Statistical Parametric Mapping version 8 
(SPM8) software was used to extract parameter estimates for the contrast of Positive 
Feedback > Negative Feedback from maximal voxels within left and right VS regions of 
interest (ROIs). Imaging acquisition protocol, task, ROIs, and preprocessing details are 
described in the Supplemental Text. Extracted parameter estimates from VS activity in each 
hemisphere were regressed on genotype (rs61826952 coded as 1 or more copies of the minor 
allele due to sample size; rs2418646 coded using an additive model for the number of C 
alleles) while co-varying for sex, and three (AA) or two (EA) ancestral principal 
components using Full Information Maximum Likelihood in MPlus v7.349. Trans-ancestral 
meta-analysis was conducted using METAL 42. To adjust for multiple comparisons, we used 
a Bonferroni-corrected p-value threshold (p<0.0125), to account for our hypothesized 4 tests 




Tables 1 (primary and secondary phenotypes of DSM-IV AD and criterion count) and 2 
(tertiary analysis of seven individual criteria) summarize the samples used in discovery and 
replication analyses. There were 7,418 (1,114 families) EA and 3,175 (585 families) AA 
individuals, respectively. In total, there were 18,586 individuals evaluated for DSM-IV AD 
in both discovery and replication samples, with 7,482 AD cases and 6,169 controls. As 
shown in Supplemental Table 1 , the primary, secondary and tertiary phenotypes were highly 
correlated with each other in both EAs and AAs, with DSM-IV AD and DSM-IV AD 
criterion count having the highest correlations with each individual criterion in both AA and 
EA subsamples (r>0.87). As shown in Supplemental Table 2, the item response analysis 
demonstrated that all criteria loaded well on a single underlying AD factor. Some criteria 
discriminated liability at the lower end of the liability distribution (e.g., Drinking more than 
intended) while others (e.g., Withdrawal, Time spent drinking, Giving up activities) 
contributed at the higher end of the severity continuum (Supplemental Text).
GWAS findings:
Regions on chromosomes 1, 2, 4, 8 and 15 reached GWS (p≤5E-8) for primary, secondary 
and tertiary phenotypes in EA and EA+AA GWAS, respectively (Table 3; Manhattan, 
quantile-quantile and regional association plots for GWS findings are in Supplemental 
Figures 3 and 4 respectively; effect sizes, standard errors and p-values for EA and AA sub-
samples and the EA+AA analysis in Supplemental Table 3). All genomic controls (lambda) 
are listed in Supplemental Table 4.
Primary phenotype (DSM-IV AD diagnosis): In EA, no GWS findings were identified. 
In the trans-ancestral meta-analysis (EA+AA), consistent with prior GWAS, rs1229984 in 
ADH1B was significantly associated with AD (p = 1.72E-8). In addition, a novel GWS locus 
was also identified on chromosome 1 (rs61826952, p=8.42E-11) in the EA+AA analysis. 
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Both the EA (p=7.73E-6) and AA (p=1.50E-07; results available upon request) subsamples 
contributed to the finding, with the same direction of effect. Conditional analyses confirmed 
that there were independent associations in the ADH1B region but not in the chromosome 1 
region (Supplemental Figure 5A, 5C).
Secondary phenotype (DSM-IV AD criterion count): Rs1229984 in ADH1B was 
associated at GWS levels in the EA and the EA+AA analysis.
Tertiary phenotypes (individual criteria): In EA, rs1229984 was associated with 
Desire to cut drinking (p=1.21E-11). Two novel regions were GWS for two individual 
DSM4 criteria: rs188227250 on chromosome 8 for Drinking more than intended 
(p=6.72E-09); rs1912461 on chromosome 15 for Time spent drinking (p=1.77E-08). For the 
trans-ancestral (EA+AA) analysis, rs1229984 was significantly associated with Desire to cut 
drinking (p = 6.01E-14) and Tolerance (p=8.06E-9). An additional GWS region on 
chromosome 2 (rs7597960, p= 1.22E-8) was noted for Time spent drinking. The regions on 
chromosome 2, 4 and 8 survived the more stringent correction for the seven criteria 
(p≤1.67E-8) while the chromosome 15 variant was GWS but did not survive the additional 
correction for multiple testing of individual criteria (i.e., p= 1.77E-8). Conditional analyses 
demonstrated that there was only one association signal in the chromosome 15 region; 
however, the possibility of a second independent signal in the chromosome 8 region could 
not be ruled out (p<0.001) (Supplemental Figures 5D and 5E). Conditional analyses also 
suggested independent associations in the chromosome 2 region (Supplemental Figures 5B).
Replication:
Rs1229984 in ADH1B was replicated in OZALC-EA for the primary AD phenotype (Table 
3); in SAGE-AA for the secondary DSM-IV AD criterion count as well as for tertiary 
phenotypes of Desire to cut drinking in SAGE-AA, SAGE-EA, and OZALC-EA, and in 
SAGE-AA, for Tolerance. Meta-analysis of all available datasets enhanced significance 
across primary and tertiary phenotypes (Table 3). The association between rs188227250 and 
Drinking more than intended was replicated in OZALC-EA and a meta-analysis of EA, 
SAGE-EA, and OZALC-EA strengthened the association (p=3.71E-09, Table 3). Although 
rs1912461 on chromosome 15 was not significantly associated with Time spent drinking in 
either the SAGE-EA or OZALC-EA samples (p> 0.12), the direction of the effect was the 
same and meta-analysis across COGA and the replication samples retained significance for 
this variant (p=2.31E-08, Table 3). Variants on chromosomes 1 and 2 did not replicate in any 
dataset (all p>0.07 or opposite direction of effects; Table 3).
Polygenic risk score analyses:
PRS derived using the EA discovery GWAS of the primary phenotype (i.e., DSM-IV AD) 
predicted 1.82% and 0.61% of the variance in AD in SAGE-EA (p=1.32E-05) and OZALC-
EA (p=7.73E-03), respectively.
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Supplemental Table 5 lists the results of gene based analyses. Two genes, OTOP1 
(P=8.73E-7) for DSM-IV criterion count, and BRINP1 (P=7.85E-8) for Drinking despite 
problem, were genome-wide significant.
Neural extension I: COGA Prospective Sample: Theta ERO
Rs1912461 on chromosome 15 for Time spent drinking was significantly associated with 
differential evoked theta power (loss-gain) in the Central (F1,1370=8.4346; p=0.0037) region 
(Supplemental Table 6). The minor allele carriers of rs1912461 manifested higher 
differentiation of gambling outcomes (loss-gain) at the anterior region of the brain 
(Supplemental Figure 6). Other variants did not survive the multiple testing correction.
Neural Extension II: Duke Neurogenetics Study: fMRI
Carriers of the minor (G) allele of rs61826952 had lower left, but not right, reward-related 
(positive feedback – negative feedback) VS activity when compared to non-carrier 
individuals in the combined and AA and EA samples (Left: trans-ancestral meta-analysis: 
beta=−0.041, p=0.008; AA: beta=−0.124, p=0.018; EA: beta=−0.033, p=0.041; Right: trans-
ancestral meta-analysis: beta=−0.01, p=0.570). Reward-related VS activity was not 
significantly associated with rs2418646 genotype (Left: trans-ancestral meta-analysis: beta=
−0.007, p=0.560; Right: trans-ancestral meta-analysis: beta=0.0003, p=0.97).
DISCUSSION
This large, family study of AA and EA individuals utilized a multi-pronged approach 
(Figure 1) to dissect the genetic underpinnings of alcohol dependence (DSM-IV AD). In 
addition to the primary phenotype of DSM-IV diagnosis of AD, and severity as captured by 
the AD criterion count, it is, to our knowledge, the largest GWAS of each DSM-IV AD 
criterion. We detected five regions with variants meeting traditional GWS criteria, of which 
four were novel (chromosomes 1, 2, 8, and 15). Notably, the chromosome 8 signal was 
replicated in an independent dataset, as was the well-known association with rs1229984 in 
ADH1B. Even when excluding the larger effect size associated with rs1229984, PRS derived 
from the EA GWAS predicted 0.61-1.82% of the variation in AD in independent datasets, 
underscoring significant polygenicity underlying liability to the disorder. Analyses of two 
reward-related neural phenotypes also showed associations with two GWS variants.
Consistent with several prior studies 6, rs1229984 in ADH1B was associated with DSM-IV 
AD. Although GWS was only noted in the trans-ancestral (EA+AA) analysis, as shown in 
Supplemental Table 7, rs1229984 was associated with the AD criterion count and criteria 
indexing physiological dependence and Desire to cut drinking at GWS levels, and with other 
AD criteria at nominal levels of significance. Despite the robust relationship between this 
functional variant and AD, its relatively low minor allele frequency necessitates fairly large 
samples to detect a GWS effect for a binary trait, as was shown in a recent meta-analysis of 
DSM-IV AD 6. However, for DSM-IV AD criterion count, rs1229984 was GWS in both the 
EA and EA+AA analyses. Similar to another study 16, we found that while rs1229984 was 
associated with each individual criterion (EA all p<3.61E-04; EA+AA all p<4.54E-05), the 
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association was stronger with certain DSM-IV AD criteria. Consistent with Hart et al., 
Tolerance was strongly associated with rs1229984 (p=8.06E-09 in EA+AA). However, the 
additional GWS associations with Desire to cut drinking in our study differs from the prior 
study which used a sequential regression approach to identify Withdrawal and Drinking 
more than intended as additional criteria related to rs1229984 in EA, and Time spent 
drinking in AA. However, another study of 1,130 individuals of Jewish descent reported 
associations between rs1229984 and both Tolerance and Desire to cut drinking 50. Across 
these studies, the most robust association signal for rs1229984 appears to arise from 
Tolerance, which is notably an index of excessive consumption and consistent with the role 
of ADH1B in other studies of non-problem alcohol intake 51. Plausibly, the strong findings 
with Desire to cut drinking might also support this as epidemiological studies have shown 
this criterion to index liability to less severe AD (Supplemental Table 2; Supplemental 
Figure 7), and therefore, serve as a marker of excessive drinking, rather than severe 
pathology and impairment 10,52-54. Differences in associations with other criteria could stem 
from the relative severity of individual criteria in each dataset or their relationship with 
excessive drinking.
The GWS findings for the other loci are novel and have not been previously reported for AD 
or related phenotypes, although these regions have been linked to some neuropsychiatric 
diseases/traits. The region on chromosome 1 was previously linked to cerebrospinal fluid 
biomarker level 55, migraine 56, illegal substance dependence 57, and neuroticism 58. This 
region encompasses gene RABGAP1L, with many other genes nearby (Supplemental Figure 
4A). RABGAP1L is broadly expressed in brain regions and showed association with 
cerebrospinal fluid biomarker levels55, and migraine 56. Other genes near this region seem 
interesting too, e.g. KIAA0040, which is downstream of this region, was associated with 
alcohol dependence59. The chromosome 2 region is in a gene desert (Supplemental Figure 
4B) and has been linked to cognitive test scores 60, ADHD symptom count 61, ADHD 62, 
current smoking 63, and juvenile myoclonic epilepsy 64. The region on chromosome 8 has 
been linked to bipolar disorder 65. The only gene near the chromosome 8 region is FAM84B 
(Supplemental Figure 4D), however, this gene doesn’t seem to be related any 
neuropsychiatric diseases. The chromosome 15 region harbors some non-coding RNAs 
(Supplemental Figure 4E) and was previously linked to the rate of cognitive decline 55, 
ADHD 66, and major depression 67. Thus, despite our discovery of novel loci, much further 
study is needed to investigate the role of these variants in the etiology of alcohol dependence 
and related traits.
In our data, the chromosome 1 variant showed nominal association with multiple AD criteria 
and the criterion count, but none at GWS levels. However, a highly correlated variant 
(rs1890881) was associated at GWS with a phenotype representing dependence on alcohol 
or illicit drugs (cannabis, cocaine, sedatives, stimulants, opioids) in the same sample (see 
accompanying paper by Wetherill et al). It is possible that this variant is associated with 
overall liability to AD and dependence on other drugs but to a lesser extent with AD severity 
as indexed by a single continuous criterion count. Research has noted that mere summation 
does not capture the heterogeneity underlying AD severity, where constellations of criteria 
could result in meaningful individual differences 10. Prior latent class analyses aimed to 
parse out such groups of individuals with unique sets of criteria including in a subset of 
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these data 9. However, assessment of the genomic underpinnings of such heterogeneous 
groups of individuals would require extremely large sample sizes. The chromosome 8 
variant, rs188227250, was uniquely associated with Drinking more than intended 
(Supplemental Table 7). In epidemiological studies and in COGA (Supplemental Table 2), 
this criterion is endorsed quite frequently by individuals with AD, and also by those who do 
not meet criteria for DSM-IV AD and thus, might index lower severity. Indeed, in IRT 
analyses, this criterion had the lowest difficulty as indicated by the item characteristic curves 
in Supplemental Figure 7. In contrast, the finding on chromosomes 2 and 15, while GWS for 
Time spent drinking were also associated with Giving up activities (at nearly GWS for 
chromosome 15), both highly correlated criteria indicative of high difficulty, and thus, risk 
for DSM-IV AD 9. In addition to Withdrawal, we previously found these criteria to 
distinguish a highly heritable high-risk group of individuals at risk for AD from those in 
both low and moderate-risk groups. Thus, as shown in Supplemental Figure 7, while the 
chromosome 8 finding potential maps to lower AD severity, the chromosome 2 and 15 
findings potentially indicate greater severity. However none of these loci were GWS for our 
AD criterion count measure, which is commonly used as an index of severity. These results 
are consistent with the argument that that the validity of an individual criterion, and its 
impact on impairment may rely heavily on the other criteria that are endorsed alongside it 10. 
Importantly, these results underscore that novel information can be gained from studying 
individual criteria that index differing levels of AD severity that may operate 
discontinuously.
Gene based analysis identified two genome-wide significant genes for two different 
phenotypes. OTOP1 was associated with DSM-IV criterion count. This gene is related to 
maintaining metabolic homeostasis but it is not well-studied. BRINP1 showed association 
with Drinking despite problems. This gene is mostly expressed in brain regions and has been 
linked to schizophrenia68,69; cognition disorders55, and Parkinson’s disease70. Further 
studies are needed to test its role in AD.
Previous studies indicate that AD may be related to variations in the brain’s reward system 
71, including decreased reward-network volume 72 and differential neural activity in reward 
circuitry 73-75. In the COGA Prospective Sample, minor allele carriers of rs1912461 showed 
greater differentiation in frontal evoked theta power between loss and gain feedback trials in 
an EEG-based Monetary Gambling Task. Prior studies have found lower reward-related 
theta power in alcoholics and in high-risk offspring of alcoholics than controls performing 
the same task 47,76. Frontal theta response underlies a variety of cognitive processes 77,78 
including reward processing 79-81. Moreover, it has recently been proposed that frontal theta 
reflects a promising mechanism through which cognitive control may be enacted by 
invoking a shift from habitual-based striatum responses to deliberative prefrontal-based 
control of behavior 82. Furthermore, the frontal-central theta power difference between loss 
and gain conditions may reflect the need for cognitive control to process goal-relevant 
information, such as decision making and action selection, based on choice-relevant 
information (approach-avoidance, reward-punishment, success-failure, etc.) for optimal 
functioning in the environment 82. In this study, the COGA Prospective participants were 
included in the COGA discovery GWAS. We, therefore, examined the sensitivity of our 
discovery findings to exclusion of these overlapping individuals from the Prospective 
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sample. The resulting GWAS found that while statistical significance decreased in some 
instances due to the decrease in sample size, the overall results remained highly consistent 
(e.g., for the EA-only finding of Drinking more than intended, the p-value decreased from 
6.72E-09 to 3.61E-08; data not shown), indicating that the overlapping subjects were not 
solely responsible for the GWS findings from the discovery GWAS.
In the Duke Neurogenetics Study, rs61826952 minor allele carriers had decreased VS 
activity to positive versus negative feedback in a number-guessing fMRI task. Increased VS 
activity and dopamine release to non-alcohol reward have been associated with substance 
use initiation and problematic drinking 25,83-85. In contrast, studies of AD reported relatively 
reduced VS activity to non-alcohol reward 86,87 and heightened activity to alcohol cues 88. 
These apparently disparate findings can be integrated with stage-based theories of addiction, 
which hypothesize that initial problematic use is associated with the positively reinforcing 
aspects of a substance, while later compulsive use is driven by negative reinforcement and 
diminished cognitive control, resulting from changes in neural plasticity induced by chronic 
alcohol use 89 (see also Wetherill et al accompanying paper). Thus, results from the college-
based Duke Neurogenetics Study suggested that the minor allele of rs61826952 may protect 
from AD by reducing VS-related reward drive, thereby diminishing the likelihood of 
initiating problematic drinking behavior.
Replication of individual variants/genes other than those involved in alcohol metabolism can 
be challenging and notably influenced by heterogeneity across samples, ascertainment 
approach, definitions of affected and unaffected, and even nuanced differences in interview 
instruments 17. For instance, although families ascertained for AD were included in the 
replication samples, OZALC had samples ascertained for heavy smoking and drinking (as 
well as sibships ascertained merely for large pedigree size), and SAGE included two 
subsamples recruited for nicotine and cocaine dependence. In addition, unlike the prior large 
AD GWAS by Gelernter and colleagues 19, we excluded individuals with ≥2 abuse or 
dependence criteria for alcohol or any illicit drug from our unaffected group 19. This may 
have led to a greater degree of genetic separation between affecteds and unaffecteds in the 
current analysis and contributed to the lack of replication. Despite these potential 
differences, for 2 of the 5 loci (rs1229984 and rs188227250), meta-analyses across samples 
yielded more significant associations. In addition, the PRS analyses found that the 
aggregated effect of variants in regions other than the ADH cluster and the ALDH2 locus 
significantly contributed to AD liability in these diversely ascertained samples. While the 
proportion of explained variance is modest, it is consistent with other PRS analyses 90 and 
supports the generalizability of our findings at a polygenic level.
We also examined whether our analyses supported recent findings from Kranzler et al., who 
conducted a GWAS of alcohol use disorders defined using International Classification of 
Disease (ICD) codes derived from the electronic health records of individuals participating 
in the Million Veterans Project4. In this multi-ancestral sample of 274,424 predominantly 
male veterans, Kranzler et al identified 18 genome wide significant loci for AUD as well as 
for the consumption subscale of the Alcohol Use Disorders Identification Testkit (AUDIT-
C). Their signal for rs1229984 was also noted in our COGA GWAS. In addition, modest 
evidence for directional and statistical support was also noted for rs12639940 on 
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chromosome 4 (p=0.03; COGA-EA), and rs2961816 on chromosome 5 (p=0.04; COGA EA
+AA).
Our findings should be considered within the context of a few key limitations. First, despite 
being large, it is evident that our sample is underpowered to detect loci of modest effect. 
However, our sample was considerably larger than in our prior efforts in a subset of these 
data (e.g., 7-9) and one GWS SNP from those prior studies, previously linked to a latent class 
representing high-risk for AD9, continued to be nominally associated with DSM-IV AD in 
the current analysis (rs17484734, prior p =4.1E-8, current p=8.77E-5) but two other 
borderline significant variants were not as strongly associated in the current larger sample 
(rs11035102, for Desire to cut back9: prior p = 7.3E-8, current p=0.002; rs12903120, for AD 
criterion count8: prior p=5.45E-8, current p=0.03). Second, some of our GWS loci had low 
minor allele frequencies which may also have limited replication efforts. Third, our AA 
subsample, while utilized in the EA+AA analysis, was too small to report on individually, 
due to the strict definition of AD affecteds. Larger discovery GWAS of non-EA samples is 
much needed.
In summary, our study highlights the importance of utilizing a variety of phenotypes, 
including individual dependence criteria in locus discovery for AD. The heterogeneity that 
underlies the diagnosis of AD due to the various combinations of individual criteria that can 
be endorsed to meet diagnostic criteria, is also true for major depression disorder (MDD), 
and has been shown to hinder GWAS 91. While significant increases in sample size can 
potentially overcome this heterogeneity (as has been shown in the GWAS of MDD 92), the 
study of individual criteria, alongside diagnosis and severity, can provide a more detailed 
characterization of common and specific genetic influences on aspects of AD, especially 
when viewing individual criteria as psychometric indices of various cut-points of AD 
liability, and may eventually shape individualized treatment based on criterion profiles and 
other related features, over and above a mere diagnosis of AD.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1:



















Discovery COGA 880 (61.70) 951 (25.45) 3,175 (46.58) 2,411 (62.01) 2,438 (28.47) 7,418 (47.53)
Replication Yale-Penn 1,524 (60.50) 485 (29.69) 2,010 (53.08) - - -
SAGE 387 (59.17) 330 (39.09) 930 (46.24) 630 (52.70) 758 (34.17) 1,708 (38.82)
OZALC - - - 1,650 (62.24) 1,206 (46.10) 3,345 (53.69)
Total 2,791 1,767 6,115 4,691 4,402 12,471
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Table 2:







Sample # Case # Control # Case # Control
1
Tolerance COGA 1,110 2,024 3,348 3,958
Yale-Penn 1,192 818 - -
SAGE 353 577 777 930
OZALC - - 2,274 1,071
2
Withdrawal COGA 514 2,616 1,259 6,046
Yale-Penn 694 1,316 - -
SAGE 200 730 257 1,451
OZALC - - 478 2,867
3
Drinking more than intended COGA 1,317 1,817 3,826 3,480
Yale-Penn 1,525 485 - -
SAGE 507 421 1,074 631
OZALC - - 2,055 1,290
4
Desire to cut drinking COGA 1,436 1,701 2,896 4,413
Yale-Penn 1,411 599 - -
SAGE 425 505 601 1,107
OZALC - - 1,420 1,925
5
Giving up activities COGA 578 2,558 1,437 5,871
Yale-Penn 1,201 809 - -
SAGE 215 715 274 1,434
OZALC - - 246 3,099
6
Time spent drinking COGA 546 2,590 1,533 5,776
Yale-Penn 1,004 1,006 - -
SAGE 251 679 354 1,354
OZALC - - 668 2,677
7
Drinking despite problems COGA 784 2,351 2,163 5,144
Yale-Penn 989 1,021 - -
SAGE 310 619 741 966
OZALC - - 1,180 2,165
1: Tolerance. Need for markedly increased amounts of alcohol to achieve intoxication or desired effect; or markedly diminished effect with 
continued use of the same amount of alcohol.
2: Withdrawal. The characteristic withdrawal syndrome for alcohol; or drinking (or using a closely related substance) to relieve or avoid withdrawal 
symptoms.
3: Drinking more than intended. Drinking in larger amounts or over a longer period than intended.
4: Desire to cut drinking. Persistent desire or one or more unsuccessful efforts to cut down or control drinking.
5: Giving up activities. Important social, occupational, or recreational activities given up or reduced because of drinking.
6: Time spent drinking. A great deal of time spent in activities necessary to obtain, to use, or to recover from the effects of drinking.
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7: Drinking despite problems. Continued drinking despite knowledge of having a persistent or recurrent physical or psychological problem that is 
likely to be caused or exacerbated by drinking.
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